Mid-term efficacy of sacral nerve stimulation for the treatment of chronic constipation.
10.3760/cma.j.cn441530-20210719-00288
- Author:
Chen Xiang HE
1
;
Shi Sen LI
2
;
Kun Li DU
2
;
Shao Qing LIU
2
;
Bo ZHANG
3
;
Fan FENG
2
;
Jian Yong ZHENG
2
Author Information
1. Department of Gastrointestinal Surgery, Xijing Hospital, Xi'an 710032, China He Chenxiang is now working at Department of General Surgery, Shanghai 10th People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.
2. Department of Gastrointestinal Surgery, Xijing Hospital, Xi'an 710032, China.
3. No.4 Department of Anorectal Surgery, the Mayinglong Coloproctological Hospital of Xi'an, Xi'an 710005, China.
- Publication Type:Journal Article
- Keywords:
Bilateral implantation;
Constipation;
Sacral nerve stimulation
- MeSH:
China;
Constipation/therapy*;
Humans;
Middle Aged;
Quality of Life;
Retrospective Studies
- From:
Chinese Journal of Gastrointestinal Surgery
2021;24(12):1073-1078
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the mid-term efficacy of sacral nerve stimulation (SNS) for chronic constipation. Methods: A descriptive case series study was conducted. Patients with chronic constipation were treated in Xijing Hospital of Digestive Disease from February 2013 to December 2018 were retrospectively enrolled. The types of constipation were confirmed based on colon slow transit test, anorectal manometry and defecography in Xi'an Mayinglong Coloproctological Hospital. This study has been registered in China clinical trial registry (Registration No.: ChiCTR-ROC-16008945). Case inclusion criteria: (1) constipation was diagnosed according to Rome III criteria; (2) traditional treatment, including education, diet adjustment, laxative, biofeedback treatment, failed for at least 1 year; (3) there were no constipation-related organic diseases. After excluding neurogenic diseases, including spinal cord injury and multiple sclerosis, 21 patients were included in this study. There were 10 males and 11 females, with an average age of 50.9 (14-76) years. After the relevant examination and evaluation of patients, they underwent percutaneous nerve evaluation (PNE). If patient experienced a good response to PNE after 2 or 3 weeks (≥50%), permanent SNS implantation was performed. The improvement of clinical symptoms and quality of life between the baseline, PNE, and latest follow-up time points were compared. Improvement of clinical symptoms, including autonomic stool frequency per week, autonomic stool days per week, defecation time, visual analogue scale (VAS, lower score indicates more serious symptoms) score and Cleveland clinic constipation score (CCCS, higher score indacates more serious symptoms) criteria. The change of quality of life was scored by SF-36 questionnaires (the higher score indicates better quality of life). Results: Of 21 patients, 18 (85.7%) experienced significant improvement in symptoms with PNE, and 2 patients discontinued treatment due to their dissatisfaction. Sixteen patients (76.2%) received permanent SNS implantation, two of whom underwent bilateral PNE implantation. These patients were followed-up for mean 56 (34-72) months. The treatment was continuously effective in 13 patients (61.9%), including 3 of ODS, 1 of STC and 9 of mixed constipation. Compared with baseline, the score of constipation patients receiving permanent SNS implantation at latest follow-up was shown. The median autonomic stool frequency per week increased from 1.0 (0-7) to 7.5 (0-10) (P<0.001), the median autonomic stool days per week increased from 1.0 (0-7) d to 4.5 (0-7) d (P<0.001), the median defecation time decreased from 19.0 (8-40) minutes to 4.0 (3-31) minutes (P<0.001), the median CCCS decreased from 20.0 (13-30) to 9.0 (6-30) (P<0.001), and the median VAS score increased from 9.0 (7-40) to 80.0 (15-90) (P<0.001). The values of the 8 parts of the SF-36 questionnaire increased (all P<0.05). Conclusion: SNS implantation is safe and has obvious effects on severe constipation with stable mid-term efficacy.
